Sarepta under new pressure as a competitor files with FDA for Duchenne drug

Sarepta Therapeutics is in more trouble.

The Japanese drugmaker NS Pharma said Wednesday that the paperwork required to seek approval for a new drug to treat Duchenne muscular dystrophy was submitted to the U.S. Food and Drug Administration.

If approved, the NS Pharma drug, called viltolarsen, would be the first treatment for children born with Duchenne caused by a mutation in the DNA sequence known as exon 53.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In